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Introduction. Sexual dysfunction (SD) and hyperprolactinemia are frequently reported in patients with psychotic disorders and
havethe potential for severe complicationsbut investigations inmales are particularly scarce. The primary aimswere to determine
the prevalence of SD and hyperprolactinemia in male patients and to investigate whether associations exist between SD and
prolactin levels. Methods. Cross-sectional data were obtained at discharge from the hospital or 6 weeks after admittance for
patientsacutelyadmitted forpsychosisandtreated withasecond-generationantipsychotic drug. Results. Halfthepatientsreported
diminishedsexualdesireandmorethanathirdreported erectile andejaculatorydysfunctionswithnodiﬀerences amongthedrugs.
More than half the sample was hyperprolactinemic. No association was found between prolactin levels and SD. Conclusion.H i g h
rates of SD and hyperprolactinemia were found in male patients and should be a treatment target. SD and hyperprolactinemia
were not correlated.
1.Introduction
Active psychosis aﬀects most aspects of normal functioning
and has been ranked the third most disabling disorder in
the general population, and more disabling than paraplegia,
blindness, or HIV infection [1]. The life-time prevalence of
any psychotic disorder is about 3 in 100 persons [2]. In a
substantial proportion of cases, the disorders are chronic and
life long. The presence of psychosis will in most instances
indicatetheuseofantipsychoticdrugs.Boththenatureofthe
disorders and antipsychotic drug treatment can profoundly
aﬀect sexual functioning.
Main tolerability issues related to antipsychotic drug use
have traditionally been the extrapyramidal syndrome (EPS)
associated with the ﬁrst-generation (typical) antipsychotics,
and metabolic adverse eﬀects associated mainly with the
second-generation (atypical) agents [3, 4]. Sexual dysfunc-
tion (SD) has received far less attention, although these side
eﬀects have been reported among the most discomforting
ones by patients with schizophrenia [5, 6]. SD is impor-
tant also as it has negative impact on medication adherence.
Antipsychotic-induced hyperprolactinemia is commonly re-
gardedasafrequentcauseofSD.Asdemonstratedinareview
by Byerly et al. [7], the ﬁndings of diﬀerent studies are
conﬂicting, however, with regards to associations between
hyperprolactinemia and sexual side eﬀects. While diﬀer-
ential propensities among second-generation antipsychotics
(SGAs) in causing hyperprolactinemia are well documented
[8], diﬀerences among the SGAs in causing SD are less
investigated. Studies addressing male SD speciﬁcally in
psychosis are particularly scarce. In one study, SD has been
reported to aﬀect almost half the sample of outpatients with
schizophrenia and to adversely aﬀect their quality of life [9].
Several research questions of clinical relevance thus re-
main unresolved, and studies in clinically relevant samples
are called for.
The primary aims of the present study were to determine
the prevalenceof SD and hyperprolactinemia, and to investi-
gatewhetherassociationsexistbetweenSDandprolactinlev-
els in male patients with psychosis. Secondary aims were to
disclose whether diﬀerences exist among second-generation
antipsychotics (SGA) with regards to SD.2 Advances in Urology
2.Materialsand Methods
The materials and methods used have been described in
more detail in a previous publication [10]. The Bergen psy-
chosis project (BPP) is a pragmatic, randomized trial com-
paring SGAs in the treatment of psychosis. The present study
reports results from the BPP from the time of discharge or
6 weeks after admission if not discharged from hospital. To
ensure a clinically relevant sample, the patient recruitment
focused on all patients with psychosis acutely admitted to
the emergency ward. Patients were recruited from March
2004 until February 2009. All patients were recruited from
Haukeland University Hospital, Division of Psychiatry, with
a catchment population of about 400,000. The BPP was
approved by the Regional Committee for Medical Research
Ethics, and the Norwegian Social Science Data Services. The
BPP was publicly funded and has not received any ﬁnancial
or other support from the pharmaceutical industry.
The Regional Committee for Medical Research Ethics
allowed eligiblepatients to be includedbefore informed con-
sent was provided, thus entailing a clinically relevant repre-
s e n t a t i o ni nt h es t u d y .P a t i e n t sf r o m1 8t o6 5y e a r so fa g e
were eligibleforthestudy iftheywere acutelyadmitted tothe
emergency ward for symptoms of psychosis as determined
by a score of ≥4 on one or more of the items delusions, hal-
lucinatorybehavior,grandiosity,suspiciousness/persecution,
or unusual thought content from the Positive and Negative
SyndromeScale(PANSS)[11].EligiblepatientsmettheICD-
10 [12] diagnostic criteria for schizophrenia, schizoaﬀective
disorder, acute and transient psychotic disorder, delusional
disorder, drug-induced psychosis, bipolar disorder except
manic psychosis, and major depressive disorder with psy-
choticfeatures. The diagnoseswere determinedbythe hospi-
tal’spsychiatrists orspecialistsinclinicalpsychology.Patients
were excluded from the study if they were unable to use oral
antipsychotics because a depot formulation was indicated,
were suﬀering from manic psychosis or for other behavioral
or mental reasons related to the state of illness were unable
to cooperate with assessments, did not understand spoken
Norwegian, were candidates for electroconvulsive therapy as
determinedby theattending psychiatrists, orwere medicated
with clozapine, usually regarded as a ﬁnal resort, on admit-
tance. Patients with drug-induced psychoses were included
only when the condition did not resolve within a few days
and when antipsychotic drug therapy was indicated.
The patients were rated using the PANSS, the Calgary
DepressionScaleforSchizophrenia(CDSS)[13],the Clinical
Drug and Alcohol Use Scales (CDUS/CAUS)[14], the Clini-
calGlobalImpression—SeverityofIllnessscale(CGI-S)[15],
the Global Assessment of Functioning—Split Version, Func-
tions scale (GAF-F) [16], and a neurocognitive screening test
(Repeatable Battery for the Assessment of Neuropsycholog-
ical Status (RBANS)) [17]. Patients were asked also to com-
pletethepatient-administered versionoftheUKUSideEﬀect
Rating Scale (UKU-SERS Pat) [18]. The items reported here
include diminished sexual desire; erectile dysfunction; and
ejaculatory dysfunction. The patient-administered versionof
theinterview waschosentoobtainmore validresultsasclini-
cians often underestimate SD [19]. The questionsasked were
“have you experienced decreased sexual interest or decreased
sexual desire?”; “have you experienced diﬃculty in reaching
erection?”;“haveyouexperienceddiﬃcultiesinejaculation?”
T h ep a t i e n t sw e r ei n s t r u c t e dt or e p o r ts y m p t o m st h a tt h e y
attributed to their prescribed medications and use the last
weekasthetimeframeofreference.Eachitemwasratedfrom
0( n o ta ta l l )t o3wi t hi n c r e a s i n gs ev e r i tyo ft h eS Ds ym p t o m
reported. A composite mean SD score was calculated based
on the three UKU-SERS Pat items, accepting up to two mis-
sing values.
A blood sample was collected from the patients between
08 and 10am, and serum level measurements of prolactin
and antipsychotics were conducted. Drug doses were con-
verted to mean Deﬁned Daily Doses (DDDs) as developed
by the World Health Organization Collaborating Centre for
Drug Statistics Methodology [20]. The basic deﬁnition of
the DDD unit is the assumed average maintenance dose per
day for a drug used for its main indication in adults. Fifteen
(23.1%)oftheprolactin bloodsampleswere analysed at Lab-
oratory A by means of a noncompetitive immunoﬂuoromet-
ric assay (DELFIA kit by Wallac Oy, Turku, Finland). Fifty
(76.9%) of the samples were analyzed at Laboratory B using
another immunoassay kit (Immulite 2000 by Siemens Med-
ical Solutions Diagnostics, Berlin and Munich, Germany).
The cutoﬀ for hyperprolactinemia was set at 360mIU/L.
Screening for macroprolactinemia by polyethylenglycol
(PEG) precipitation was performed if prolactin levels were
above 1000mIU/L at both laboratories to identify cases with
pseudohyperprolactinemia caused by the biologically inert
macroprolactin fraction.
SPSS version 18.0 was used for statistical analyses. Mean
serumprolactinlevelsatlaboratoriesAandBwerecompared
using an independent samples t-test. Chi square exact test
was used for categorical data. To investigate the association
between prolactin levels and symptoms registered on the
rating scale, a bivariate analysis of correlation was performed
using the Spearman correlation coeﬃcient as normal distri-
bution could not be assumed. Signiﬁcance level was set at
α = 0.05.
3.Resultsand Discussion
3.1. Results. A total of 72 men were assessed. A total of 20
patients used risperidone, the corresponding ﬁgures were for
olanzapine 26, quetiapine 9, ziprasidone 13, and aripipra-
zole 1. Three patients were not prescribed antipsychotics.
The mean serum levels with standard deviations (sd) and
reference levels in nanomoles per litre were for risperidone
79.5 (58.5) (30–120), for olanzapine 107.3 (75.8) (30–200),
forquetiapine522.8(660.9)(100–800),forziprasidone129.1
(107.2) (30–200), and for aripiprazole 141 (-) (200–1300).
The mean doses in milligrams with sd were for risperidone
3.7 (1.3), for olanzapine 17.3 (6.4), for quetiapine 477.8
(204.8), for ziprasidone 98.3 (46.3); and for aripiprazole
5 (-). There were no diﬀerences among the groups with
regards to the use of concomitant medication.
The clinical characteristics and demographics are dis-
played in Table 1. The majority had a diagnosis of schiz-
ophrenia (55.6%). A total of 33 (45.8%) patients had notAdvances in Urology 3
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used antipsychotic drugs before this admittance to hospital.
With the exception of a higher CDSS sum score (6.9), in the
risperidone group versus 2.8; 3.9; 3.6; 1.0; 3.5, in the olan-
zapine, quetiapine, ziprasidone, aripiprazole, and unmed-
icated groups, respectively (one-way anova, P = 0.033),
there were no statistically signiﬁcant diﬀerences among the
drug groups. A total of 45.9% of the patients reported
diminished sexualdesire,whereas35.9%and36.1%reported
erectile and ejaculatory dysfunction, respectively (Figure 1).
There were no diﬀerences among the groups, or between the
antipsychotic na¨ ıve patients and those with prior antipsy-
chotic drug use in this regard. The mean prolactin level
was 627.9mIU/L, range 59.0–3019.0. There was no signiﬁ-
cant diﬀerence among the laboratories with regards to mean
prolactin levels (t-test: P = 0.25; mean diﬀerence 68.3; 95%
CI −286.0–422.6). The risperidone group had the highest
mean prolactin level (1250.8mIU/L) followed by olanza-
pine (483.0mIU/L), ziprasidone (379.6mIU/L), quetiapine
(236.2mIU/L), the unmedicated group (184.7mIU/L), and
aripiprazole (70.0mIU/L,one-wayanova: P<0.001).Atotal
of 56.3% of the patients had hyperprolactinemia, and there
were signiﬁcant diﬀerences among the groups following the
same pattern as for the mean prolactin levels (chisquare:
P<0.001). A total of 18.5% had prolactin levels above
1080mIU/L, the proportion being 57.9% in the risperi-
done group with signiﬁcant diﬀerences among the groups
(chisquare: P<0.001). There was no association between
prolactin level and the composite SD score (Spearman’s
correlation coeﬃcient r = 0.141; P = 0.29, Figure 2).
Also, there was no association between SD and the PANSS
total and subscale scores; the CDSS, the CGI, the GAF-F,
neurocognitive test score, or DDDs of the diﬀerent drugs.
For risperidone but not the other antipsychotics, there was
a signiﬁcant correlation between serum prolactin level and
drug doses of risperidone in DDD equivalents (Spearman’s
correlation coeﬃcient r = 0.598; P = 0.011).
3.2. Discussion. T h es a m p l ew a sh e t e r o g e n e o u sb o t hw i t h
regards to diagnoses and stage of illness and about half the
sample was antipsychotic drug na¨ ı v ea ta d m i t t a n c ew h i c h
most likely represents patients with ﬁrst-episode psychosis.
The sample should accordingly be clinically relevant. The
main ﬁndings of the present study were the very high rates
of SD and hyperprolactinemia in patients treated with SGAs,
and the lack of association between the two. About half the
patients reported diminished sexual desire and more than a
third reported erectile and ejaculatory dysfunction. The rate
of SD is in correspondence with the ﬁndings of Olfson et al.
[9] in their sample of male outpatients with schizophrenia.
The mean age of the sample was more than 10 years older
than in the BPP sample and seemed to be selected for the
assessment of SD speciﬁcally, making the results of the more
diagnostically and clinically heterogeneous BPP sample even
more startling. SD is perceived by patients as among the
more severe side eﬀects of antipsychotics and is associated
with poor drug adherence [5, 6]. Noncompliance is one
leadingcauseofrelapseandrehospitalisation inpatientswith
schizophrenia, the latter representing the largest part of the
schizophrenia treatment costs [21].The proportionswithSD
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are accordingly alarmingly high both in terms of individual
suﬀering and economic burden to society. With regards to
the secondary aim, no diﬀerences among the drug groups
were found. Bobes et al. [22] found in their sample of 636
schizophrenia outpatients a lower risk of SD in quetiapine,
treated patients compared to those treated with haloperidol,
risperidone, or olanzapine. The diﬀerent ﬁndings across
the studies may be related to diﬀerent samples, treatment
settings, or an insuﬃcient sample size in the BPP to detect
actual diﬀerences among the drug groups.
More than half the sample was hyperprolactinemic, and
about one ﬁfth had prolactin levels more than 3 times the
upper threshold, none of which were caused by the bio-
logically inert macroprolactin fraction. There were diﬀer-
ences among the drug groups, with risperidone-treated
patients having the highest prolactin levels and the highest
proportions with hyperprolactinemia. Hyperprolactinemia
has received new attention lately as potential long-term
complications have been pointed to, including osteoporosis
and carcinogenic eﬀects [7, 8]. No association was found in
the present study between prolactin levels and SD. This is in
linewithpreviousﬁndingsfromourresearchgroup[23].Ina
recent study in schizophrenia patients switched to a second-
generation antipsychotic drug, positive correlation between
prolactin levels and diminished sexual desire was found
for men [24]. Nakonezny et al. [25] found an association
between serum prolactin level and SD for prolactin but not
quetiapine in their 6-week randomized trial. Byerly et al.
[7]r e p o r td i ﬀering results among diﬀerent studies regarding
relationship between prolactin levels and SD in men, as only
about half the studies reviewed found support for such a
relationship. Data on SD in ﬁrst-episode psychosis has been
published from theEUFESTstudy, indicating inﬂuence from
the psychotic disorder itself as well as from prolactin on at
least some aspects of SD [26].
The primary strengths of the present study are the clin-
ically relevant sample of consecutively recruited male psy-
chotic patients, and the very comprehensive characterisation
of the sample. The measurement of serum levels of the anti-
psychotics used adds special value to the study too.
Some limitations should be mentioned, however. The
cross-sectional designdoesnotallowforanalysesofcausality.
The sample size may have been too small to detect actual
associations. We do not believe this to be the case, however,
as signiﬁcant correlations between hyperprolactinemia and
SD were disclosed in even smaller samples of schizophrenia
patients in the review by Byerly et al. [7]. We hypothesise
that in a heterogeneous sample such as the BPP sample, the
prolactin contribution is blurred among several other causes
of SD.
4.Conclusions
Both SD and hyperprolactinemia were very prevalent in this
sample of male psychotic patients. Based on our ﬁndings,
the phenomena should be regarded as relatively independent
entities with regards to planning appropriate actions. In
some instances, reduction of the prolactin level may also
resolve SD, whereas in other cases this may not suﬃce.
Finally, prolactin levels should be measured irrespective of
whether symptoms of SD are present or not to avoid poten-
tial long-term complications of “silent” hyperprolactinemia.
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